|
1.
|
|
15 p, 598.6 KB |
Five Year Survival Update From KEYNOTE-010 : Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC
/
Herbst, Roy S (Section of Medical Oncology. Yale Comprehensive Cancer Center. Yale University School of Medicine) ;
Garon, E.B. (David Geffen School of Medicine. University of California Los Angeles) ;
Kim, D.W. (Seoul National University Hospital. Seoul National University College of Medicine) ;
Cho, B.C. (Yonsei Cancer Center. Yonsei University College of Medicine) ;
Gervais, R. (Centre François Baclesse (Caen, França)) ;
Perez-Gracia, J.L. (Clínica Universidad de Navarra) ;
Han, J.Y. (Center for Lung Cancer. National Cancer Center) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Forster, M.D. (UCL Cancer Institute/University College London Hospitals) ;
Monnet, Isabelle (Centre Hospitalier Intercommunal de Créteil) ;
Novello, Silvia (Department of Oncology. University of Turin. Azienda Ospedaliero Universitaria San Luigi) ;
Gubens, M.A. (University of California. San Francisco) ;
Boyer, M. (Chris O'Brien Lifehouse) ;
Su, W.C. (National Cheng Kung University Hospital) ;
Samkari, A. (Merck & Co.. Inc.) ;
Jensen, E.H. (Merck & Co.. Inc.) ;
Kobie, J. (Merck & Co.. Inc.) ;
Piperdi, B. (Merck & Co.. Inc.) ;
Baas, Pieter (The Netherlands Cancer Institute (Amsterdam, Països Baixos))
Introduction: In the KEYNOTE-010 study, pembrolizumab improved overall survival (OS) versus docetaxel in patients with previously treated, advanced NSCLC with programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) ≥50% and ≥1%. [...]
2021 -  10.1016/j.jtho.2021.05.001
Journal of Thoracic Oncology, Vol. 16 Núm. 10 (october 2021) , p. 1718-1732
|
|
|
2.
|
|
11 p, 388.8 KB |
Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab
/
Arnold, D. (Instituto CUF de Oncologia (I.C.O.), Lisboa) ;
Fuchs, C. S. (Internal Medicine, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA) ;
Tabernero, Josep (Universitat Autònoma de Barcelona) ;
Ohtsu, A. (Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan) ;
Zhu, A. X (Massachusetts General Hospital (Boston)) ;
Garon, E. B. (Hematology Oncology, David Geffen School of Medicine at UCLA Translational Research in Oncology-US Network, Santa Monica, USA) ;
Mackey, J. R. (Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Canada) ;
Paz Ares, L. (Hospital Universitario 12 de Octubre (Madrid)) ;
Baron, A. D. (Division of Hematology Oncology, California Pacific Medical Center, San Francisco, USA) ;
Okusaka, T. (Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan) ;
Yoshino, Takayuki (Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan) ;
Yoon, H. H. (Division of Medical Oncology, Mayo Clinic, Rochester, USA) ;
Das, M. (Oncology, Eli Lilly and Company, Indianapolis, USA) ;
Ferry, David (Oncology, Eli Lilly and Company, Bridgewater, USA) ;
Zhang, Y (Oncology, Eli Lilly and Company, Bridgewater, USA) ;
Lin, Y (Oncology, Eli Lilly and Company, Indianapolis, USA) ;
Binder, P. (Oncology, Eli Lilly and Company, Bridgewater, USA) ;
Sashegyi, A.. (Oncology, Eli Lilly and Company, Indianapolis, USA) ;
Chau, Ian (Department of Medicine, Royal Marsden Hospital, Sutton, UK)
Ramucirumab, the human immunoglobulin G1 monoclonal antibody receptor antagonist of vascular endothelial growth factor receptor 2, has been approved for treating gastric/gastroesophageal junction, non-small-cell lung, and metastatic colorectal cancers. [...]
2017 - 10.1093/annonc/mdx514
Annals of oncology, Vol. 28 (september 2017) , p. 2932-2942
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
